Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2 positive breast cancer

被引：0
|
作者：
Le, Xiao-Feng [1 ]
Wu, Yun [1 ]
Spizzo, Riccardo [1 ]
Yoo, Suk-Young [1 ]
Wang, Jing [1 ]
Calin, George A. [1 ]
Bast, Robert C. [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4000
引用
收藏
页数：1
相关论文
共 50 条
  • [41] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [42] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [43] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [44] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [45] HER2: Beyond trastuzumab
    Hudis, Clifford
    CANCER INVESTIGATION, 2007, 25 : 4 - 5
  • [46] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [47] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [48] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [49] Dual HER2 targeting for early breast cancer
    Johnston, Stephen R. D.
    LANCET ONCOLOGY, 2013, 14 (12): : 1145 - 1146
  • [50] The Evolving Landscape of HER2 Targeting in Breast Cancer
    Moasser, Mark M.
    Krop, Ian E.
    JAMA ONCOLOGY, 2015, 1 (08) : 1154 - 1161
12345